• Industry News
  • Law & Malpractice
  • Coding & Documentation
  • Practice Management
  • Finance
  • Technology
  • Patient Engagement & Communications
  • Billing & Collections
  • Staffing & Salary

Female Rectal Exams

Article

Up until the past few weeks, I have been able to bill for a G0102 (rectal exam) for patients of either sex. However, I’ve started getting denials from Medicare. Is there a different CPT I should be using for a rectal exam on a woman? Many of these exams are associated with a yearly exam for female patients. However, some are for presenting signs and symptoms.

Question: Up until the past few weeks, I have been able to bill for a G0102 (rectal exam) for patients of either sex. However, I’ve started getting denials from Medicare. Is there a different CPT I should be using for a rectal exam on a woman? Many of these exams are associated with a yearly exam for female patients. However, some are for presenting signs and symptoms.

Answer: As far as I’m aware and can discover, Medicare and most other payers cover a digital rectal exam (DRE) for men only as part of a screening for prostate disease. Medicare will cover a DRE for men over 50 on Medicare once every 12 months and also will cover a PSA test every 12 months.

If you are doing DREs to check for colon cancer, you need to use other procedures. Medicare covers a fecal occult blood test every 12 months, a flex sig every 48 months, and a screening colonoscopy once every 24 months if the patient is at high risk, or once every 10 years but not within 48 months of a screening sig if the patient is not at high risk.

I generally find it easiest to go to the Medicare site for patients to check on benefits.

Related Videos
The importance of vaccination
The fear of inflation and recession
Protecting your practice
Protecting your home, business while on vacation
Protecting your assets during the 100 deadly days
Payment issues on the horizon
The future of Medicare payments
MGMA comments on automation of prior authorizations
The burden of prior authorizations
Strategies for today's markets
© 2024 MJH Life Sciences

All rights reserved.